Core Insights - Aurora Cannabis Inc. reported a record net revenue of $90.4 million for Q2 2026, marking an 11% increase year-over-year, driven primarily by a 15% growth in the global medical cannabis segment and a 34% increase in plant propagation revenue [6][9][10] - The company achieved an adjusted EBITDA of $15.4 million, reflecting a 52% increase compared to the same period last year, indicating strong operational performance [19][9] - Aurora maintains a strong balance sheet with $141.9 million in cash and operates a debt-free cannabis business, positioning itself well for future growth [4][9] Financial Performance - Total net revenue for Q2 2026 was $90.4 million, up from $81.1 million in Q2 2025, with medical cannabis contributing $70.5 million, which is 78% of total revenue [6][8] - Adjusted gross profit before fair value adjustments was $51.8 million, a 22% increase from $42.6 million in the prior year [7] - The adjusted gross margin before fair value adjustments improved to 61% in Q2 2026 from 54% in the prior year [7] Medical Cannabis Segment - Medical cannabis net revenue reached $70.5 million, a 15% increase year-over-year, accounting for 94% of adjusted gross profit before fair value adjustments [8][9] - International medical cannabis revenue grew by 22% to $42.7 million, highlighting Aurora's leadership in key markets [9][10] - The adjusted gross margin for medical cannabis was 69%, slightly up from 68% in the previous year, driven by cost reductions and improved production efficiency [11] Consumer Cannabis Segment - Consumer cannabis net revenue decreased by 34% to $6.9 million, attributed to a strategic focus on high-margin medical cannabis over consumer products [12][9] - The adjusted gross margin for consumer cannabis improved to 27% from 15% in the prior year, reflecting cost efficiencies [13] Plant Propagation Segment - Plant propagation revenue was $11.6 million, a 34% increase from $8.6 million in the prior year, driven by organic growth and expanded product offerings [14] - However, the adjusted gross margin for plant propagation decreased to 10% from 19% due to inventory write-offs and surplus crops [15] Operational Efficiency - Adjusted SG&A expenses rose to $35.5 million, up from $31.7 million in the prior year, primarily due to increased freight and logistics costs [16] - The company reported a net loss from continuing operations of $53.2 million, a significant decline from a net income of $1.4 million in the prior year, influenced by increased operating expenses and other costs [17] Future Outlook - For Q3 2026, Aurora expects consolidated net revenue to increase year-over-year, driven by 8% to 12% growth in the global medical cannabis segment [21] - The company anticipates maintaining strong adjusted gross margins and positive free cash flow due to improved operational performance [22][23]